Suppr超能文献

隐源性肝硬化患者血液溶酶体酸性脂肪酶活性严重降低:一项全国性多中心队列研究。

Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study.

作者信息

Angelico Francesco, Corradini Stefano Ginanni, Pastori Daniele, Fargion Silvia, Fracanzani Anna Ludovica, Angelico Mario, Bolondi Luigi, Tozzi Giulia, Pujatti Pietro Luigi, Labbadia Giancarlo, Corazza Gino Roberto, Averna Maurizio, Perticone Francesco, Croce Giuseppe, Persico Marcello, Bucci Tommaso, Baratta Francesco, Polimeni Licia, Del Ben Maria, Violi Francesco

机构信息

I Clinica Medica, Atherothrombosis Center, Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Italy; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Italy.

Gastroenterology Division, Department of Clinical Medicine, Sapienza University of Rome, Italy.

出版信息

Atherosclerosis. 2017 Jul;262:179-184. doi: 10.1016/j.atherosclerosis.2017.03.038. Epub 2017 Mar 31.

Abstract

BACKGROUND AND AIMS

Blood lysosomal acid lipase (LAL) is reduced in non-alcoholic steatohepatitis, which is the major cause of cryptogenic cirrhosis (CC); few data on LAL activity in CC do exist. We investigated LAL activity in a cohort of patients with liver cirrhosis.

METHODS

This is a multicentre cohort study including 274 patients with liver cirrhosis of different aetiology from 19 centres of Internal Medicine, Gastroenterology and Hepatology distributed throughout Italy. Blood LAL activity (nmol/spot/h) was measured with dried blood spot extracts using Lalistat 2.

RESULTS

Overall, 133 patients had CC, and 141 patients had cirrhosis by other causes (61 viral, 53 alcoholic, 20 alcoholic + viral, 7 autoimmune). Mean age was 64.2 ± 13.4 years, and 28.5% were women. Patients with CC were older compared to other aetiology-cirrhosis, with a lower Child-Turcotte-Pugh (CTP, p=0.003) and MELD (p=0.009) score, and a higher prevalence of cardio-metabolic risk factors and previous ischemic events. In the whole cohort, median LAL activity value was 0.58 nmol/spot/h, 0.49 and 0.65 in the groups of CC and known-aetiology cirrhosis, respectively (p=0.002). The difference remained significant after adjustment for white blood cells count (p=0.001). Multivariable linear regression analysis showed that CC (vs. known aetiology, Beta = -0.144, p=0.018), platelet count (Beta = 0.398, p < 0.001) and CTP score (Beta = -0.133, p=0.022) were associated with log-LAL activity. Similar results were found using MELD as covariate.

CONCLUSIONS

We found a marked reduction of LAL activity in patients with cryptogenic cirrhosis compared to the other known aetiologies. A prospective study will clarify the role of LAL in chronic liver diseases.

摘要

背景与目的

非酒精性脂肪性肝炎中血溶酶体酸性脂肪酶(LAL)减少,非酒精性脂肪性肝炎是隐源性肝硬化(CC)的主要病因;关于CC中LAL活性的数据很少。我们调查了一组肝硬化患者的LAL活性。

方法

这是一项多中心队列研究,纳入了来自意大利各地19个内科、胃肠病学和肝病学中心的274例不同病因的肝硬化患者。使用Lalistat 2通过干血斑提取物测量血LAL活性(nmol/斑/小时)。

结果

总体而言,133例患者患有CC,141例患者因其他原因患有肝硬化(61例病毒感染,53例酒精性,20例酒精性+病毒感染,7例自身免疫性)。平均年龄为64.2±13.4岁,女性占28.5%。与其他病因性肝硬化相比,CC患者年龄更大,Child-Turcotte-Pugh(CTP,p = 0.003)和终末期肝病模型(MELD,p = 0.009)评分更低,心血管代谢危险因素和既往缺血事件的患病率更高。在整个队列中,LAL活性中位数为0.58 nmol/斑/小时,CC组和已知病因性肝硬化组分别为0.49和0.65(p = 0.002)。在调整白细胞计数后,差异仍然显著(p = 0.001)。多变量线性回归分析显示,CC(与已知病因相比,β = -0.144,p = 0.018)、血小板计数(β = 0.398,p < 0.)和CTP评分(β = -0.133,p = 0.022)与log-LAL活性相关。使用MELD作为协变量也得到了类似结果。

结论

我们发现与其他已知病因相比,隐源性肝硬化患者的LAL活性显著降低。一项前瞻性研究将阐明LAL在慢性肝病中的作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验